Product Name

Emigo 4mg Tablet

Manufacturers

Zuventus Healthcare Ltd

Salt Composition

Ondansetron (4mg)

Medicine Type

drugs

Introduction

In Treatment of Nausea Emigo 4mg Tablet blocks the action of chemicals in the body that can make you feel or be sick. It is often used to prevent nausea and vomiting that may be caused by cancer chemotherapy and radiation treatment (in adults and children aged 4 years and older). It is usually taken both before and after chemotherapy or radiation. This medicine helps you recover more comfortably from these treatments. It is also effective at preventing nausea and vomiting after an operation (in adults only). The dose will depend on what you are being treated for but always take this medicine as it is prescribed.

Benefits

Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Emigo 4mg Tablet may be taken with or without food, but it is better to take it at a fixed time.

Description

Emigo 4mg Tablet is an antiemetic medicine commonly used to control nausea and vomiting due to certain medical conditions like stomach upset. It is also used to prevent nausea and vomiting caused due to any surgery, cancer drug therapy, or radiotherapy.Emigo 4mg Tablet may be used alone or with other medications and can be taken with or without food. Your doctor will suggest the appropriate dose depending on what you are taking it for. The first dose is normally taken before the start of surgery, chemotherapy, or radiotherapy. After these treatments, take any further doses as prescribed by your doctor (normally only for a few days at most). Take it regularly at the same time(s) each day to get the most benefit. Be careful not to take too much. This medicine does not relieve other side effects associated with cancer treatments. Also, it has little effect on vomiting caused by motion sickness. The most common side effects of taking this medicine include headache, diarrhea, or constipation and feeling tired. These symptoms should disappear when you stop taking the medicine. However, if these side effects bother you or do not go away, your doctor may be able to suggest ways of preventing or reducing them. Before taking this medicine, tell your doctor if you have heart or liver problems or a blockage in your stomach or intestines. Also, tell your doctor about any other medicines you might be taking, especially medicines to treat epilepsy, heart problems, cancer, and depression. These may affect, or be affected by, this medicine. If you are pregnant or breastfeeding, ask for advice from your doctor.

How To Use

Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Emigo 4mg Tablet may be taken with or without food, but it is better to take it at a fixed time.

Safety Advise

- Alcohol : CAUTION

Caution is advised when consuming alcohol with Emigo 4mg Tablet. Please consult your doctor. | - Pregnancy : CONSULT YOUR DOCTOR

Information regarding the use of Emigo 4mg Tablet during pregnancy is not available. Please consult your doctor. | - Breast feeding : CONSULT YOUR DOCTOR

Information regarding the use of Emigo 4mg Tablet during breastfeeding is not available. Please consult your doctor. | - Driving : CONSULT YOUR DOCTOR

It is not known whether Emigo 4mg Tablet alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react. | - Kidney : SAFE IF PRESCRIBED

Emigo 4mg Tablet is safe to use in patients with kidney disease. No dose adjustment of Emigo 4mg Tablet is recommended.However, inform your doctor if you have an underlying kidney disease. Limited information is available in patients taking this medicine for more than one day. | - Liver : CONSULT YOUR DOCTOR

There is limited information available on the use of Emigo 4mg Tablet in patients with liver disease. Please consult your doctor.

Drivinginteraction

CONSULT YOUR DOCTOR

Kidneyinteraction

SAFE IF PRESCRIBED

Liverinteraction

CONSULT YOUR DOCTOR

Manufacturer Address

Office No. 5119, 5th Floor, 'D' Wing, Oberoi Garden Estates, Chandivili, Andheri (E), Mumbai - 400 072.

Q A

Q. How quickly does Emigo 4mg Tablet work?::: Emigo 4mg Tablet starts working within half an hour to 2 hours. It dissolves rapidly into the bloodstream and starts showing its effect.| Q. What are the side effects of Emigo 4mg Tablet?::: The most common side effects of Emigo 4mg Tablet are constipation, diarrhea, fatigue and headache. However, these are usually not bothersome and resolve on their own after some time. Consult your doctor if these persist or worry you.| Q. When should you take Emigo 4mg Tablet?::: Emigo 4mg Tablet should be taken with a full glass of water, with or without food. It should be used exactly as per the dose and duration advised by the doctor. Usually, the first dose of Emigo 4mg Tablet is taken before the start of your surgery, chemotherapy or radiation treatment.| Q. Is Emigo 4mg Tablet a steroid?::: No, Emigo 4mg Tablet is an antiemetic and not a steroid. Emigo 4mg Tablet is a selective 5-HT3 receptor antagonist. It is prescribed for the prevention and treatment of nausea and vomiting which is commonly observed after surgery or due to cancer chemotherapy.| Q. Does Emigo 4mg Tablet work for seasickness?::: No, Emigo 4mg Tablet does not work for seasickness. This is because Emigo 4mg Tablet has very little effect on the nausea associated with motion sickness.

How It Works

Emigo 4mg Tablet is an antiemetic medication. It works by blocking the action of a chemical messenger (serotonin) in the brain that may cause nausea and vomiting during anti-cancer treatment (chemotherapy) or after surgery.

Interaction

Emigo 4mg Tablet & Montokuf 15mg Syrup :

Ondansetron may reduce the effect of Codeine. | Emigo 4mg Tablet & Acicod 10mg Tablet :

Ondansetron may reduce the effect of Codeine. | Emigo 4mg Tablet & Montokuf Plus 15mg Syrup :

Ondansetron may reduce the effect of Codeine. | Emigo 4mg Tablet & Markodin Syrup :

Ondansetron may reduce the effect of Codeine. | Emigo 4mg Tablet & Lincotuss 15mg Syrup :

Ondansetron may reduce the effect of Codeine. | Emigo 4mg Tablet & PARVODEX 65MG CAPSULE :

Ondansetron may reduce the effect of Dextropropoxyphene. | Emigo 4mg Tablet & Nalfy 10mg Injection :

Ondansetron may reduce the effect of Nalbuphine. | Emigo 4mg Tablet & Nacphin Injection :

Ondansetron may reduce the effect of Nalbuphine. | Emigo 4mg Tablet & Intapan Kit Injection :

Ondansetron may reduce the effect of Nalbuphine. | Emigo 4mg Tablet & Ruffy 20mg Injection :

Ondansetron may reduce the effect of Nalbuphine.

Marketer Details

Zuventus Healthcare Ltd | Office No. 5119, 5th Floor, 'D' Wing, Oberoi Garden Estates, Chandivili, Andheri (E), Mumbai - 400 072.

Reference

Sharkey KA, Wallace JL. Treatment of Disorders of Bowel Motility and Water Flux; Anti-Emetics; Agents Used in Biliary and Pancreatic Disease. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 12th ed. New York, New York: McGraw-Hill Medical; 2011. pp. 1341-42. | Katzung BG. Histamine, Serotonin, & the Ergot Alkaloids. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology. 11th ed. New Delhi, India: Tata McGraw Hill Education Private Limited; 2009. p. 285 | Ondansetron. Portage, IN: Monosol Rx, LLC; 1991 [revised Jul. 2010]. [Accessed 28 Mar. 2019] (online) Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022524s000lbl.pdf | Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006. Ondansetron. [Updated 2019 Feb 7]. [Accessed 20 Feb. 2020] (online) Available from: https://www.ncbi.nlm.nih.gov/books/NBK500798/ | Central Drugs Standard Control Organisation (CDSCO). [Accessed 28 Mar. 2019] (online) Available from: https://cdscoonline.gov.in/CDSCO/Drugs | Ondansetron hydrochloride [Prescribing Information]. Research Triangle Park, NC: GlaxoSmithKline; 2016. [Accessed 25 Jul. 2024] (online) Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020103s035_020605s019_020781s019lbl.pdf